NEW YORKAntigenics Inc. announced positive final results from a phase II
study of the company’s personalized heat shock protein cancer vaccine
Oncophage (HSPPC-96) in patients with metastatic melanoma. The study included
39 evaluable patients with stage IV melanoma who underwent surgery to remove
tumor tissue, which was used to produce their personalized Oncophage vaccine.
Of the 28 patients who had residual disease after surgery, two had a
complete clinical response after Oncophage treatment and survived tumor free
for at least 2 more years. Three patients who had tumor remaining after
surgery had extended disease stabilization (5 to 9 months). Of the 11
patients rendered disease free by surgery, three had long-term disease-free
survival (8 to 21 months). The results were published in the Journal of
Clinical Oncology (October 15, 2002).